Under acidic conditions, it transforms into an active structure and combines with the SH group of the proton pump ((HK)-ATPase) to inhibit the activity of the enzyme and inhibit gastric acid secretion; it can inhibit the (HK)-ATPase activity of microsomes in dog gastric mucosa; it has an inhibitory effect on the acid secretion of dog gastric mucosal parietal cells stimulated by histamine, acetylcholine and gastrin; it significantly inhibits the acid secretion and nocturnal gastric acid secretion caused by gastrin and insulin stimulation in healthy adults; it has a significant inhibitory effect on 24-hour gastric acid secretion and gastric pH; it has a significant inhibitory effect on gastroesophageal reflux in patients with reflux esophagitis; it has a continuous inhibitory effect on acid secretion caused by various stimuli in rats and gastric pouch dogs; it promotes the healing of chronic gastric and duodenal ulcers in rats; it has a significant inhibitory effect on gastric ulcers, duodenal ulcers and reflux esophagitis caused by various reasons.

This product is a quinolone antibacterial drug, which has strong antibacterial effect on Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Proteus, Salmonella typhi, Salmonella paratyphi, Shigella, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter, Serratia marcescens, Pseudomonas aeruginosa, Neisseria meningitidis, Haemophilus influenzae, Moracata, Legionella pneumophila, Neisseria gonorrhoeae, etc. It also has moderate antibacterial effect on Gram-positive cocci such as Staphylococcus and hemolytic Streptococcus. The mechanism of action of this product is to inhibit the bacterial DNA gyrase and thus kill bacteria.

It has lipid-lowering, anti-atherosclerotic and antioxidant effects

It has lipid-lowering, anti-atherosclerotic and antioxidant effects

It has lipid-lowering, anti-atherosclerotic and antioxidant effects

It has lipid-lowering, anti-atherosclerotic and antioxidant effects

It has lipid-lowering, anti-atherosclerotic and antioxidant effects

It has lipid-lowering, anti-atherosclerotic and antioxidant effects

It has lipid-lowering, anti-atherosclerotic and antioxidant effects

It has lipid-lowering, anti-atherosclerotic and antioxidant effects

Selective serotonin reuptake inhibitors (SSRIs) can effectively inhibit neurons from taking up serotonin from the synaptic cleft, increasing the amount of this neurotransmitter available for actual use in the cleft, thereby improving emotional states and treating depressive disorders.

This drug belongs to Class 2A, i.e., a β1-receptor blocker without partial agonist activity (cardioselective β-receptor blocker). It has a selective blocking effect on β1-receptors, no PAA (partial agonist activity), and no membrane stabilizing effect. Its effect on blocking β-receptors is approximately equal to that of propranolol (PP), and its selectivity for β1-receptors is slightly inferior to that of atenolol. Metoprolol's effects on the heart, such as slowing heart rate, inhibiting cardiac contractility, reducing automaticity, and delaying atrioventricular conduction time, are similar to those of propranolol and atenolol (AT). Its effect on reducing elevated blood pressure and heart rate during exercise testing is also similar to that of PP and AT. Its contraction effect on vascular and bronchial smooth muscle is weaker than that of PP, so its effect on the respiratory tract is also smaller, but still stronger than that of AT. Metoprolol can also reduce plasma renin activity.